Literature DB >> 17373722

Orofacial automatisms induced by acute withdrawal from high-dose midazolam mimicking nonconvulsive status epilepticus in a child.

David Epstein1, Marc Difazio.   

Abstract

Nonconvulsive Status Epilepticus (NCSE) is not uncommon in children, and can be challenging to diagnose and treat. Etiologies vary widely and include infection, trauma and acute withdrawal from medications such as anticonvulsants. We report a child who experienced orofacial dyskinesias concerning for NCSE after withdrawal from high dose benzodiazepines andopiates. Automonic signs typically associated with sedative withdrawal were absent and treatment with benzodiazepines did not improve his symptoms. Diagnostic testing was negative, including electroencephalogram, and resolution was complete within five days. Our case demonstrates the orofacial dyskinesias that may occur during sedative medication withdrawal, and highlights potential confusion with non-convulsive status epilepticus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373722     DOI: 10.1002/mds.21260

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Midazolam Responsive Oculogyric Crisis, Oral Automatisms, Akinesia and Rigidity Induced by Sedation Withdrawal in a Child.

Authors:  Robertino Dilena; Alberto Giannini; Alberto Cappellari; Sophie Guez; Alberto Priori
Journal:  Mov Disord Clin Pract       Date:  2014-06-06

2.  Association between clinical factors and orofacial dyskinesias in anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Hailun Hang; Liuyu Lin; Danhui Li; Jin Li; Jingping Shi; Jie Lu
Journal:  Brain Behav       Date:  2022-05-27       Impact factor: 3.405

Review 3.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.